Fasoracetam

Fasoracetam is a synthetic nootropic of the racetam family, sharing the class-defining 2-pyrrolidinone core while carrying its own cyclohexanecarbonyl and piperidine substituents. It was originally developed in Japan in the 1990s under the code names NS-105 and LAM-105 and was first investigated for vascular dementia and age-related cognitive decline before that early program was set aside ^[2]. Interest was later renewed when the compound, redesignated NFC-1 and AEVI-001, advanced into modern clinical research for attention-deficit hyperactivity disorder ^[1][4].

Among racetams the compound is unusual because its cognitive profile rests on metabotropic glutamate receptor (mGluR) modulation and on regulation of the GABA-B system rather than on direct AMPA-receptor potentiation. That distinctive pharmacology has made it a subject of interest both as a cognitive enhancer and as a research tool for probing glutamatergic signaling ^[1].

In research applications fasoracetam is best known from an open-label, single-blind, placebo-controlled study in adolescents with ADHD who harbored mutations in mGluR-network genes, where treatment was associated with measurable symptom improvement ^[1]. It has also been characterized pharmaceutically; analyses of its crystalline and hydrate solid-state forms were framed around its potential as an anti-Alzheimer agent ^[3], and it appears in systematic reviews of novel, non-stimulant compounds for ADHD ^[4].

Fasoracetam is not an approved medicine in the United States or Europe and remains an investigational compound; it is sold on the research and nootropics market, most often as a monohydrate powder or in capsules. Its regulatory status is that of an unapproved drug rather than a licensed pharmaceutical, and its evidence base, while more developed than that of most racetams, is still early.

Fasoracetam is unscheduled and legal to buy as a research chemical in most countries (US, UK, EU), though no agency has approved it for human use. Because it works on GABA-B, it can in theory interact with GABAergic stuff, so be careful pairing it with phenibut, baclofen, benzodiazepines, or alcohol. Human trials haven't turned up liver toxicity or serious adverse events, but there's no long-term data. Skip it if you react badly to racetams, and avoid it in pregnancy or breastfeeding. Since it modulates mGluRs, go careful if you have a seizure history or take anticonvulsants. It's not a controlled substance.

Fasoracetam was originally synthesized in Japan by Nippon Shinyaku, where it was studied under the code NS-105 during the 1990s as a candidate for vascular dementia and related cognitive impairment. Development was discontinued after the compound failed to show sufficient benefit in that program, and it lay largely dormant for years. It was subsequently revived under the designations NFC-1 and AEVI-001, when researchers pursued it as a modulator of metabotropic glutamate receptor signaling for adolescents with attention-deficit hyperactivity disorder who carry variants in mGluR-network genes. This second life makes fasoracetam one of relatively few racetam-class compounds to have been carried into controlled human trials, and a frequently cited example of a genetics-guided, precision-medicine approach to cognition.

Fasoracetam has a strong reputation among nootropic users as a calmer, less stimulant-like racetam, often described as delivering focus and motivation with an anxiolytic quality that suits overactive minds. It is especially popular for the theory-driven practice of rebuilding GABA-B tone after phenibut or baclofen, reflecting its documented up-regulation of GABA-B receptors with repeated dosing. Researchers value it as one of the few racetams with both a controlled clinical trial and fully characterized solid-state pharmacology, unlike many analogues that were never formally studied. The honest caveat is that its clearest human evidence comes from a small ADHD study concentrated in a genetically defined subgroup, so broad cognitive claims remain investigational. It stands out as an unusually well-characterized member of an otherwise loosely documented compound class.